Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 8OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm Metastasis 7Stomach Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 50Paclitaxel 48Cisplatin 39Gemcitabine 31Erlotinib Hydrochloride 30Radiotherapy 28Docetaxel 24Taxes 21Specimen Handling 20Magnetic Resonance Spectroscopy 20Vinorelbine 16Pemetrexed 12Etoposide 12Bevacizumab 12Radiation 10Gefitinib 10aldesleukin 8Platinum 8Bortezomib 8Biopsy 8Vinblastine 7Azacitidine 71,2-diaminocyclohexaneplatinum II citrate 7pembrolizumab 6atezolizumab 6Observation 6Immunoglobulin G 6Disulfides 6Cyclophosphamide 6Chemotherapy, Adjuvant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Non-Small-Cell Lung × trastuzumab deruxtecan × Clear all
NCT07012031 2026-05-13

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

National Cancer Institute (NCI)

Phase 1/2 Recruiting
37 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡